This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
April 06, 2016
Strongbridge Biopharma plc Announces Presentation at 15th Annual Needham Healthcare Conference
April 05, 2016
Altimmune Expands Clinical Development Team
April 04, 2016
Strongbridge Biopharma plc Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference
April 01, 2016
Nexstim Plc Appoints John Liedtky as VP of Commercialisation, General Manager US and announces the retirement of John Hardin
March 31, 2016
Nexstim Plc provides key update on Phase III NICHE stroke therapy trial
March 24, 2016
Strongbridge Biopharma plc Reports Full-Year 2015 Financial Results
March 21, 2016
Onxeo Announces Establishment of U.S. Subsidiary
March 18, 2016
AstraZeneca acquires all rights to Orexo´s OX-CLI project
March 10, 2016
TARGOVAX ANNOUNCES ENCOURAGING INTERIM RESULTS WITH RAS SPECIFIC PEPTIDE VACCINE IN RESECTED PANCREATIC CANCER
March 09, 2016
Cancer Company Aprea Closes EUR 46 Million (~USD 51 Million) Series B Financing